STOCK TITAN
  1. Home
  2. Sec-filings
  3. KYMR
  4. [144] Kymera Therapeutics, Inc. SEC Filing

Kymera officer plans $1.3M stock sale from options

Kymera Therapeutics officer Jeremy Chadwick filed a Rule 144 notice to sell 10,879 shares acquired via stock option exercises, following prior 10b5-1 sales in June 2026.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. (KYMR) is the issuer for which officer Jeremy Chadwick has filed a notice of proposed sale of common stock under Rule 144. The notice covers 10,879 shares of common stock to be sold on or after September 2, 2026, through Morgan Stanley Smith Barney, with the shares being acquired via exercise of stock options and sold for cash over the next three months.

In the prior three months, Chadwick reported additional Rule 144 sales of Kymera common stock, including 12,500 shares for $1,222,072.50 on June 23, 2026, 5,510 shares for $499,646.80 on June 18, 2026, and 48,883 shares for $4,410,837.77 on June 17, 2026, each identified as 10b5-1 sales.

Positive

  • None.

Negative

  • None.
Shares proposed for sale 10,879 shares Common stock to be sold under Rule 144 beginning on or after September 2, 2026
Proposed sale value $1,295,144.95 Aggregate market value listed for 10,879 shares in the new Rule 144 notice
Recent 10b5-1 sale June 23, 2026 12,500 shares for $1,222,072.50 Common stock sale by Jeremy Chadwick under a 10b5-1 plan
Recent 10b5-1 sale June 18, 2026 5,510 shares for $499,646.80 Common stock sale by Jeremy Chadwick under a 10b5-1 plan
Recent 10b5-1 sale June 17, 2026 48,883 shares for $4,410,837.77 Common stock sale by Jeremy Chadwick under a 10b5-1 plan
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144"
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
10b5-1 regulatory
"10b5-1 Sales for JEREMY CHADWICK 500 North Beacon Street"
A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.
Exercise of Stock Options financial
"Common | 09/02/2026 | Exercise of Stock Options | Issuer"

FAQ

What does the Form 144 filing disclose for Kymera Therapeutics (KYMR)?
The filing discloses that officer Jeremy Chadwick intends to sell 10,879 shares of Kymera common stock under Rule 144, with the shares to be acquired via exercise of stock options and sold for cash over the next three months starting September 2, 2026.

How many Kymera Therapeutics (KYMR) shares is Jeremy Chadwick planning to sell in this notice?
Jeremy Chadwick plans to sell 10,879 shares of Kymera Therapeutics common stock. The shares are to be received upon the exercise of stock options and then sold for cash under Rule 144, beginning on or after September 2, 2026.

What is the estimated value of the Kymera (KYMR) shares in the new Form 144 sale?
The notice lists an aggregate market value of $1,295,144.95 for the 10,879 shares of Kymera common stock proposed to be sold under Rule 144, based on the information provided in the securities information section.

What Kymera Therapeutics (KYMR) stock sales has Jeremy Chadwick made in the past three months?
Over the past three months, Jeremy Chadwick reported 10b5-1 sales of Kymera common stock: 12,500 shares for $1,222,072.50 on June 23, 2026, 5,510 shares for $499,646.80 on June 18, 2026, and 48,883 shares for $4,410,837.77 on June 17, 2026.

How will the Kymera (KYMR) shares in this Form 144 be acquired before sale?
The shares will be acquired through the exercise of stock options. The remarks state that the securities to be sold were and will be received upon option exercises over the next three months, with the dates of acquisition and payment matching the dates of exercise and sale.

Is the Kymera (KYMR) Form 144 sale tied to a trading plan?
The new 10,879-share proposed sale is disclosed as an exercise of stock options and cash sale under Rule 144. The filing also lists prior 10b5-1 sales in June 2026 but does not label the new proposed sale itself as a 10b5-1 transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR